VIDEO: Management of type 2 diabetes no longer just a ‘glucose-centric approach’

Issue: December 2022

ByRegina Schaffer

ByJuan P. Frias, MD

Fact checked byRichard Smith

BOSTON — In this Healio video exclusive, Juan P. Frias, MD, discusses his presentation on newer treatment options for type 2 diabetes at the Cardiometabolic Health Congress.

Frias, medical director and principal investigator at Velocity Clinical Research in Los Angeles, said that “over the last 2 decades, the philosophy of the management of type 2 diabetes has changed.”

Development of drugs such as SGLT2 inhibitors and GLP-1 receptor agonists has led to moving from a “glucose-centric approach to one where we’re clearly concerned about improving glycemic control, but also about cardiorenal health, about the importance of liver health and reducing liver fat, and improving cardiovascular outcomes” as well as “improving overweight and obesity in our patients with type 2 diabetes,” Frias said.

Watch the video for more.

Reference:

Frias JP. Emerging treatment options for diabetes. Presented at: Cardiometabolic Health Congress; Oct. 19-22, 2022; Boston.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interviews

Disclosures: Frias reports receiving research support from 89bio, Akero, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Intercept, IONIS, Janssen, Madrigal, Metacrine, Merck, NorthSea Therapeutics, Novartis, Novo Nordisk, Oramed, Pfizer, Poxel and Sanofi; serving on advisory boards or consulting for 89bio, Akero, Altimmune, Axcella Health, Becton Dickenson, Boehringer Ingelheim, Carmot Therapeutics, Echosens, Eli Lilly, Gilead, Intercept, Metacrine, Merck, Novo Nordisk, Pfizer and Sanofi; and serving on the speakers bureau for Eli Lilly, Merck and Sanofi.

Cardiometabolic Health Congress

Read more

VIDEO: Management of type 2 diabetes no longer just a ‘glucose-centric approach’

Reference:

Related Content